Post by Lonza

We have acquired the rights to Nona Biosciences’ transferrin receptor (TfR1) blood-brain barrier technology and expanded our strategic collaboration to develop next-generation brain delivery solutions for central nervous system (CNS) disorders. The blood-brain barrier is a highly selective protective system that, while essential for safeguarding brain function, limits the ability of many therapeutic molecules to reach the brain. By combining Nona’s technology with Lonza's biologics development and bioconjugation capabilities, we aim to help customers overcome this challenge and advance the next generation of CNS therapies. Read more: https://ow.ly/BVlX50Zjvhe #Lonza #CDMO #Biologics #IntegratedBiologics #Bioconjugation #AdvancedSynthesis #Licensing #PharmaceuticalManufacturing